Arbutus Biopharma Corp Sublease Income
Arbutus Biopharma Corp (ABUS) reported Sublease Income of $200.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SubleaseIncome · last filed 2021-03-04
- Arbutus Biopharma Corp sublease income for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp sublease income for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp sublease income for the quarter ending 2019-06-30 was $100.00K, a 400.00% increase year-over-year.
- Arbutus Biopharma Corp sublease income for the quarter ending 2019-03-31 was $100.00K.
- Arbutus Biopharma Corp sublease income for fiscal 2019 was $200.00K, a 0.00% change from fiscal 2018.
- Arbutus Biopharma Corp sublease income for fiscal 2018 was $200.00K.
| Period end | Sublease Income 3 month | Sublease Income 6 month | Sublease Income 9 month | Sublease Income 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $0.00 derived: sum of 2 quarters · filed 2021-03-04 | $100.00K derived: sum of 3 quarters · filed 2021-03-04 | $200.00K 10-K · filed 2021-03-04 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $100.00K derived: sum of 2 quarters · filed 2019-11-06 | $200.00K 10-Q · filed 2019-11-06 | $300.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2019-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $200.00K 10-Q · filed 2019-08-05 | $300.00K derived: sum of 3 quarters · filed 2020-03-05 | $380.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2019-03-31 | $100.00K 10-Q · filed 2019-05-06 | $200.00K derived: sum of 2 quarters · filed 2020-03-05 | $280.00K derived: sum of 3 quarters · filed 2020-03-05 | $300.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $180.00K derived: sum of 2 quarters · filed 2020-03-05 | $200.00K derived: sum of 3 quarters · filed 2020-03-05 | $200.00K 10-K · filed 2020-03-05 |
| 2018-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $100.00K derived: sum of 2 quarters · filed 2019-11-06 | $100.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $20.00K 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |